Effective clearance of methotrexate using high-flux hemodialysis membranes

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
S M WallT Madden

Abstract

We report the first series demonstrating effective clearance of methotrexate using acute intermittent hemodialysis with a high-flux dialyzer. The study was performed on six patients, two females and four males aged 13 to 72 years. All were patients at M.D. Anderson Cancer Center. Patients were dialyzed for 4 to 6 hours daily using a Fresenius F-80 membrane (Fresenius Inc, Walnut Creek, CA). Following the initiation of dialysis, there was a reduction in arterial and venous serum concentration of methotrexate with time. Mean plasma clearance of methotrexate during dialysis in these six patients was 92.1 +/- 10.3 mL/min. One patient who was nearly functionally anephric was studied in detail. In this patient, following a high dose of methotrexate (7.2 g/m2), approximately 63% of this dose was cleared with 6 hours of hemodialysis. With subsequent dialysis performed daily for 6 hours, the drug was cleared completely in 5.6 +/- 0.3 days (n = 7 separate methotrexate treatments). A reduction in plasma methotrexate concentration from 1,733 +/- 40 micromol/L 1 hour postinfusion to less than 0.3 micromol/L in 5 to 6 days was observed for these seven separate treatments. We conclude that significant clearance of methotrexate can be achieved...Continue Reading

Citations

May 20, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C D Flombaum, P A Meyers
Jun 9, 2006·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·O M Escobosa SánchezT Acha García
Jun 1, 2006·Expert Review of Neurotherapeutics·Myke R GreenMarc Chamberlain
Nov 10, 2006·Acta Clinica Belgica·O BoeyD Verbeelen
Nov 23, 2007·Nature Clinical Practice. Nephrology·Kevin W Finkel, John R Foringer
Jun 24, 2008·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Silas W Smith, Lewis S Nelson
Nov 21, 2009·Expert Opinion on Biological Therapy·Daniel M Patterson, Siow Ming Lee
Mar 24, 2012·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Kimberly N FlynnDouglas L Smith
Sep 28, 2017·Current Opinion in Critical Care·Mitchell H RosnerMark A Perazella
Jan 7, 2020·Canadian Journal of Kidney Health and Disease·Ann YoungJeffrey Perl
Aug 28, 2020·CA: a Cancer Journal for Clinicians·Mitchell H RosnerMark A Perazella
Nov 13, 2003·American Journal of Physiology. Renal Physiology·Carsten KneuerWalther Honscha
Aug 24, 2007·Journal of the European Academy of Dermatology and Venereology : JEADV·J SeneschalA Taieb
May 7, 2010·Journal of Intensive Care Medicine·Baruch S FertelDavid S Goldfarb
Oct 8, 2013·Annals of Hematology·Anna BertramBernhard M W Schmidt
May 27, 2014·BMJ Case Reports·Mohamed Said AbdelsalamIrfan Maghfoor
Aug 9, 2016·The Oncologist·Scott C HowardR Donald Harvey
Aug 21, 2016·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Jennifer S StewardPolly E Kintzel
May 18, 2016·Nature Reviews. Disease Primers·Vikas R DharnidharkaSylvain Choquet
Dec 23, 1999·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·F K MatzkiesK H Rahn
Nov 28, 2012·Clinical Rheumatology·Raoul BergnerChristian Löffler
Sep 1, 2017·Clinical and Experimental Nephrology·Shigeo HorieSatoru Muto
May 1, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·H BoulangerG Deray
Feb 28, 2002·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Carlo BasileAngelo Semeraro
Sep 12, 2000·Bone Marrow Transplantation·K van BesienR Hoffman
Jun 24, 2006·The Oncologist·Brigitte C Widemann, Peter C Adamson
Jul 10, 2019·Kidney Research and Clinical Practice·Mitchell H Rosner, Mark A Perazella
May 13, 2004·Cancer·Brigitte C WidemannPeter C Adamson
Apr 22, 2011·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Kang Min LeeJun Ah Lee
Feb 11, 2021·Clinical Lymphoma, Myeloma & Leukemia·Huong Truong, Nelson Leung
Oct 18, 2006·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Areena SwarupH Ralph Schumacher
May 4, 1999·The American Journal of Medicine·M A Perazella
Feb 2, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N JanusV Launay-Vacher
Nov 15, 1997·Rheumatic Diseases Clinics of North America·J L Hillson, D E Furst
Aug 30, 2001·Critical Care Clinics·M Kapoor, G Z Chan
Aug 7, 2021·Nefrología : publicación oficial de la Sociedad Española Nefrologia·Justine SolignacMickaël Bobot

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
M LeblancJ Cardinal
Journal of Clinical Pharmacology
C S LeeT J Fuller
© 2021 Meta ULC. All rights reserved